- Protecting Food. Protecting People.
- Annual Report: Achievements Building a Healthier Future
- AMR is Rising — Stewardship Demands Global Leadership
News
In line with our public health mission, bioMérieux and BioFire Defense, a bioMérieux company, are mobilizing Ebola diagnostics to support ongoing efforts related to the current Ebola outbreak in Africa.
Swipe for more stories
-
Measuring to reduce environmental impact: how bioMérieux is acting across our diagnostic solutions
Our products’ environmental performance is a core pillar of our commitment to protecting the planet. For several years, bioMérieux has been implementing a continuous improvement approach based on Life Cycle Assessments (LCAs) of our diagnostic solutions. The goal is to measure our products’ impact on the climate and environment across the entire value chain — from manufacturing and customer use to end-of-life management. -
First-Quarter 2026 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026. Consolidated sales totaled €984 million in the first quarter of 2026. -
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
bioMérieux, a world leader in in vitro diagnostics, announces the publication of a multi-country health economic analysis assessing the impact of deploying fast identification and antimicrobial susceptibility testing (ID/AST) early in the care pathway for patients with bloodstream infections at high-risk of sepsis.
Enabling Decision-Making
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19